The $1\alpha,25(\text{OH})_2\text{D}_3$ Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF- κ B and MAPK Signaling

This article was published in the following Dove Press journal:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Jingjing Zhu^{1,2}
John PH Wilding^{2,3}

¹Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China; ²Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, Merseyside, UK; ³Clinical Sciences Centre, University Hospital Aintree, Liverpool, Merseyside, UK

Purpose: Key research findings suggest that attenuating metaflammation in adipose tissue might be a strategic step to prevent the metabolic syndrome and its associated disease outcomes. The anti-inflammatory effects of $1\alpha,25(\text{OH})_2\text{D}_3$ have been confirmed in our previous studies, but adverse effects induced at high concentrations restrict its potential clinical translation. Two synthetic $1\alpha,25(\text{OH})_2\text{D}_3$ analogs ZK159222 and ZK191784 have manifested promising tissue-specific immunomodulatory actions, but limited data are available on adipose tissue. Hence, in this study, we investigated whether ZK159222 and ZK191784 act on preadipocytes or macrophages to attenuate metaflammatory responses via modulating inflammatory and metabolic signaling in macrophage-induced preadipocytes.

Methods: Preadipocyte-specific effects of ZK159222 and ZK191784 on macrophage-induced preadipocytes were tested by pre-incubating and incubating preadipocytes with the analogs and MacCM. Separately, macrophage-specific effects of both analogs on macrophage-induced preadipocytes were tested by incubating preadipocytes with analog-MacCM or MacCM. The effects of $1\alpha,25(\text{OH})_2\text{D}_3$ were also examined and set as the positive control. Metaflammatory responses were determined as the concentrations and gene expression of major pro-inflammatory cytokines including IL-1 β , IL-6, IL-8, MCP-1 and RANTES, measured using ELISA and qPCR. Inflammatory and metabolic signaling including NF- κ B and MAPK were probed using Western blotting.

Results: ZK159222 and ZK191784 act on preadipocytes and macrophages to decrease the secretion and gene expression of the major pro-inflammatory cytokines in macrophage-induced preadipocytes. The anti-inflammatory effects were at least as potent as $1\alpha,25(\text{OH})_2\text{D}_3$, and no preadipocyte apoptosis was induced at high concentrations. In addition, mostly at high concentrations, both analogs moderately decreased the phosphorylation of relA, p44/42 and p38 MAPK in macrophage-induced preadipocytes.

Conclusion: ZK159222 and ZK191784 act on macrophages and preadipocytes to attenuate metaflammatory responses in macrophage-induced preadipocytes, by decreasing phosphorylation of relA/NF- κ B, p44/42 and p38 MAPK.

Keywords: vitamin D, metaflammatory response, relA, p44/42, p38

Introduction

The metabolic syndrome (MetS) is a constellation of interrelated risk factors including central obesity, insulin resistance, dyslipidemia and hypertension, which have been considered to promote the development of type 2 diabetes, cardiovascular disease, and

Correspondence: John PH Wilding
Tel +44 151 529 5885
Fax +44 151 529 5888
Email j.p.h.wilding@liverpool.ac.uk

even a plethora of cancers.^{1,2} A growing body of evidence suggests that metaflammation in adipose tissue contributes to the onset and progress of MetS.^{3,4} Metaflammation is mainly characterized as adipose tissue expression of various pro-inflammatory cytokines stimulated by M1 macrophage infiltration.⁵ Therefore, attenuating adipose tissue metaflammation might be a strategic step to prevent MetS and its associated disease outcomes.

The immunomodulatory properties of $1\alpha,25(\text{OH})_2\text{D}_3$ have suggested it may have a role in treating inflammatory diseases.⁶ $1\alpha,25(\text{OH})_2\text{D}_3$ has also long been known to influence metabolic and immune functions of adipose tissue.⁷ Moreover, the anti-inflammatory properties of $1\alpha,25(\text{OH})_2\text{D}_3$ in adipose tissue metaflammation were confirmed in our previous studies.^{8,9} However, adverse effects, i.e. calcium release-activated apoptosis, potentially restrict its clinical translation.^{8,10} Thus, during recent decades, attempts have been made to synthesize $1\alpha,25(\text{OH})_2\text{D}_3$ analogs with preservation of immunomodulatory properties but elimination of calcium homeostasis disruption.¹¹

In this study, we primarily investigated whether two synthetic $1\alpha,25(\text{OH})_2\text{D}_3$ analogs (namely ZK159222 and ZK191784) act on preadipocytes or macrophages to attenuate metaflammatory responses in macrophage-induced preadipocytes. In addition, both inflammatory and metabolic signaling including NF- κ B and mitogen-activated protein kinase (MAPK) were probed to elucidate the underlying anti-inflammatory mechanisms.

Materials and Methods

Reconstitution of ZK159222, ZK191784 and $1\alpha,25(\text{OH})_2\text{D}_3$

ZK159222, ZK191784 (kindly provided by Bayer AG, Germany) and $1\alpha,25(\text{OH})_2\text{D}_3$ (ENZO Life Sciences, USA) were reconstituted in dimethyl sulfoxide to a concentration of 2.4×10^{-5} M and then diluted in media (indicated as below) to final concentrations of 10 nM and 1 μ M.

Macrophage Culture and Stimulation

The human THP-1 monocytic cell line was kindly provided by Professor Helen R Griffiths (Aston University, UK) and cultured in RPMI-1640 medium (Sigma-Aldrich, UK) with 10% fetal bovine serum at 37°C with 5% CO_2 . Upon reaching a cell density of 1×10^6 cells/mL, supernatants were replaced with 100 nM phorbol 12-myristate 13-acetate (Sigma-Aldrich, UK) in RPMI-1640 medium with

10% fetal bovine serum to differentiate the monocytes to macrophages for 48 h. Subsequently, supernatants were aspirated and 1 μ g/mL lipopolysaccharide in RPMI-1640 medium was added to polarize the macrophages to pro-inflammatory M1 dominant phenotype.¹² The M1 dominant macrophages were cultured in RPMI-1640 medium for macrophage-conditioned medium (MacCM), or incubated with ZK159222 (10 nM and 1 μ M), ZK191784 (10 nM and 1 μ M) or $1\alpha,25(\text{OH})_2\text{D}_3$ (10 nM) in RPMI-1640 medium for VD-MacCM. All the supernatants were collected after 24 h, filtered through 0.22 μ m filters and stored at -80°C (the THP-1 cell line was originally purchased by Professor Helen Griffiths in Birmingham from the UK Government laboratory in Porton Down that has ethical approval for the development of such cell lines. For specific details, please refer to *Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes* (DOI: 10.1016/j.freeradbiomed.2012.05.026), which was published in 2009 by Professor Griffiths' research group, firstly described the THP-1 cell line as having been purchased from Health Protection Agency Culture Collections (Porton Down, Salisbury, UK); all RPMI-1640 media used in culture or stimulation were supplemented with 1% penicillin/streptomycin).

Preadipocyte Culture and Stimulation

Commercially available human white preadipocytes derived from subcutaneous adipose tissue of a 44 years old female Caucasian subject with a body mass index of 21 kg/m² (PromoCell, Germany), were cultured to confluence as previously described.⁹ Following this, supernatants were aspirated and the preadipocytes were pre-incubated in preadipocyte growth medium (PromoCell, Germany) or with ZK159222 (10 nM and 1 μ M), ZK191784 (10 nM and 1 μ M) or $1\alpha,25(\text{OH})_2\text{D}_3$ (10 nM) in preadipocyte growth medium for 48 h. Subsequently, supernatants were aspirated and the preadipocytes were incubated with 25% RPMI-1640 medium (the control) or 25% MacCM or 25% MacCM along with ZK159222 (10 nM and 1 μ M), ZK191784 (10 nM and 1 μ M) or $1\alpha,25(\text{OH})_2\text{D}_3$ (10 nM) in preadipocyte growth medium for 24 h. Preadipocyte and supernatant collection was conducted after the incubation. Separately, when confluence was reached, supernatants were aspirated and the preadipocytes were incubated with 25% RPMI-1640 medium (the control), 25% MacCM or VD-MacCM (indicated as above) in preadipocyte growth medium for 24 h before preadipocyte and supernatant collection (all preadipocyte growth media used in culture or stimulation were supplemented with 100

U/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B).

Measurement of Metaflammatory Responses

Proteins were extracted from the preadipocytes, and content measured as previously described.¹³ The concentrations of interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 and regulated on activation, normal T cell expressed and secreted (RANTES) in the supernatant were measured independently in duplicate using human ELISA kits following the manufacturer's instructions (R&D Systems, UK) and SPECTROstar Nano Microplate Reader (BMG LABTECH, Germany), normalized to the total cell protein and presented as ng (cytokine)/mg(cell protein).

RNA was extracted from Trizol-lysed preadipocytes and converted to cDNA using cDNA synthesis kit (Bio-Rad, UK). The relative gene expression of IL-1β, IL-6, IL-8, MCP-1 and RANTES were measured as Ct value independently in duplicate using TaqMan gene expression assays (Applied Biosystems, UK), qPCR core kit following the manufacturer's instructions (Eurogentec, Belgium) and Stratagene Mx3005P instrument system, normalized to the internal reference PPIA,¹⁴ and presented as fold change relative to control using the $2^{-\Delta\Delta Ct}$ formula.¹⁵

Western Blotting

Proteins were extracted from the preadipocytes and measured as previously described.¹³ The intracellular densities of relA, phosphorylated relA, p44/42 MAPK, phosphorylated p44/42 MAPK, p38 MAPK and phosphorylated p38 MAPK were measured using the method previously described,¹³ and normalized to the internal control vinculin. All the antibodies used (New England BioLabs; Abcam, UK) were diluted according to the manufacturer's instructions. The phosphorylation level of relA, p44/42 MAPK and p38 were calculated as the ratio of phosphorylated relA to relA, phosphorylated p44/42 MAPK and phosphorylated p38 MAPK to p38 MAPK, respectively, and presented as fold change relative to control.

Statistical Analysis

Data were analyzed using one-way ANOVA and followed by Tukey's test for individual comparison (GraphPad Prism 5, USA). A value of $P < 0.05$ was regarded as statistically

significant. The results were confirmed by three independent experiments and shown as mean $\pm$ SEM.

Results

ZK159222 and ZK191784 Act on Preadipocytes to Reduce the Major Pro-Inflammatory Cytokines Secreted from Macrophage-Induced Preadipocytes

Metaflammatory responses were stimulated by inducing preadipocytes with 25% MacCM. IL-1β, IL-6, IL-8, MCP-1 and RANTES were selected as major pro-inflammatory cytokines expressed in macrophage/MacCM-induced preadipocytes in keeping with published studies.^{16–21} The ELISA results show that secretion of the major pro-inflammatory cytokines was increased by 13 ~ 387-fold from MacCM-induced preadipocytes (Figure 1A).

To test whether ZK159222, ZK191784 or $1\alpha,25(\text{OH})_2\text{D}_3$ act on preadipocytes to attenuate the metaflammatory responses in macrophage-induced preadipocytes, preadipocytes were pre-incubated with ZK159222, ZK191784 and $1\alpha,25(\text{OH})_2\text{D}_3$ to boost their efficacy as formally established,¹³ and then incubated with ZK159222, ZK191784 and $1\alpha,25(\text{OH})_2\text{D}_3$ along with induction of MacCM.

In accordance with our previous study,⁹ 10 nM of $1\alpha,25(\text{OH})_2\text{D}_3$ generally reduced the major pro-inflammatory cytokines secreted from MacCM-induced preadipocytes by 43 ~ 81%. 10 nM of ZK159222 and ZK191784 also exhibited significant anti-inflammatory effects as the overall pro-inflammatory secretions from MacCM-induced preadipocytes were decreased by 28 ~ 69% and 27 ~ 68%, respectively. Tukey's test indicates that both synthetic analogs reduced the secretion of the major pro-inflammatory cytokines as effectively as $1\alpha,25(\text{OH})_2\text{D}_3$ (Figure 1A).

Preadipocytes started to undergo apoptosis in 2–4 h when pre-incubated with 1 µM of $1\alpha,25(\text{OH})_2\text{D}_3$ (data not shown). However, 1 µM of ZK159222 and ZK191784 significantly and similarly reduced the overall pro-inflammatory secretion from MacCM-induced preadipocytes by 23 ~ 67% and 29 ~ 69% (Figure 1A).

ZK159222 and ZK191784 Act on Preadipocytes to Inhibit the Major Pro-Inflammatory Cytokines Expressed in Macrophage-Induced Preadipocytes

The qPCR results show that gene expression of the major pro-inflammatory cytokines was increased by 13 ~ 1933-

Panel A

Figure 1 Continued.

fold in MacCM-induced preadipocytes. Consistent with our previous study,⁹ 10 nM of 1 α ,25(OH) $_2$ D $_3$ universally inhibited the major pro-inflammatory cytokines expressed in MacCM-induced preadipocytes by 61 ~ 88%. Likewise, 10 nM of ZK159222 and ZK191784 decreased the overall pro-inflammatory gene expression in MacCM-induced preadipocytes by 31 ~ 68% and 67 ~ 89%, though ZK159222 appeared less potent. Moreover, 1 μ M of ZK159222 and ZK191784 similarly inhibited the overall pro-inflammatory gene expression by 47 ~ 74% and 57 ~ 76% (Figure 1B).

ZK159222 and ZK191784 Act on Preadipocytes to Decrease Phosphorylation of Inflammatory and Metabolic Signaling in Macrophage-Induced Preadipocytes

During adipose tissue metaflammation, the NF- κ B signaling is activated via phosphorylation of the transcription factor relA in

the nucleus.^{22,23} The Western blotting results show that intracellular levels of relA were not affected, but the phosphorylation was increased by 1.2-fold in MacCM-induced preadipocytes. In accordance with our previous study,⁹ 10 nM of 1 α ,25(OH) $_2$ D $_3$ decreased relA phosphorylation by 39% in MacCM-induced preadipocytes. Although relA phosphorylation was not affected by 10 nM of ZK159222 or ZK191784, 1 μ M of both synthetic analogs significantly and consistently decreased the phosphorylation by 17% and 17%, respectively (Figure 2A and B) (for MacCM-induced preadipocytes co-incubated with 1 α ,25(OH) $_2$ D $_3$, ZK159222 and ZK191784, the quantifications were calculated as the percentages of $\frac{\text{the relative fold changes of (MacCM-induced preadipocytes - the co-incubation)}}{\text{the relative fold changes of MacCM-induced preadipocytes}}$).

The MAPK signaling are required for physiological metabolic adaptation, but inappropriate activation has been associated with the development of MetS.²⁴ As conventional MAPKs, p44/42 and p38 are activated via phosphorylation in the cytoplasm.²⁵ In this study, though intracellular levels of p44/42 and p38 MAPK were not affected, the phosphorylation of both MAPKs in MacCM-induced preadipocytes were

Panel B

Figure 1 Preadipocyte-specific effects of ZK159222, ZK191784 and 1 α ,25(OH) $_2$ D $_3$ on the major pro-inflammatory cytokines secreted and expressed in macrophage-induced preadipocytes. Preadipocytes were pre-incubated in preadipocyte growth medium or with ZK159222 (10 nM and 1 μ M), ZK191784 (10 nM and 1 μ M) or 1 α ,25(OH) $_2$ D $_3$ (10 nM) in preadipocyte growth medium for 48 h, and then incubated with 25% RPMI-1640 medium (the control) or 25% MacCM or 25% MacCM along with ZK159222 (10 nM and 1 μ M), ZK191784 (10 nM and 1 μ M) or 1 α ,25(OH) $_2$ D $_3$ (10 nM) in preadipocyte growth medium for a further 24 h. Supernatants and preadipocytes were collected after the incubation. (Panel A) The concentrations of (a) IL-1 β , (b) IL-6, (c) IL-8, (d) MCP-1 and (e) RANTES were measured using ELISA. (Panel B) The relative gene expression of (a) IL-1 β , (b) IL-6, (c) IL-8, (d) MCP-1 and (e) RANTES were measured using qPCR. Data were analyzed using one-way ANOVA. The results are shown as means $\pm$ SEM for groups of 6 and confirmed by 3 independent experiments. A significant difference to control is indicated by ***($p < 0.001$); to MacCM by # ($p < 0.05$), ###($p < 0.01$) and ###($p < 0.001$); among ZK159222, ZK191784 and 1 α ,25(OH) $_2$ D $_3$ by &($p < 0.05$), &&($p < 0.01$) and &&&($p < 0.001$).

increased by 0.2-fold and 1.9-fold, whereas 10 nM of 1 α ,25(OH) $_2$ D $_3$ decreased p44/42 and p38 MAPK phosphorylation by 30% and 76%. For the analogs, only 1 μ M of ZK159222 de-phosphorylated p44/42 MAPK (by 31%) in MacCM-induced preadipocytes. By contrast, (10 nM and 1 μ M) both analogs universally decreased p38 MAPK phosphorylation by 27% to 58%, though ZK159222 appeared least effective (Figure 2A, C and D).

ZK159222 and ZK191784 Act on Macrophages to Reduce the Major Pro-Inflammatory Cytokines Secreted and Expressed in Macrophage-Induced Preadipocytes

To test whether ZK159222, ZK191784 or 1 α ,25(OH) $_2$ D $_3$ (VD) also act on macrophages to attenuate the

metaflammatory responses in macrophage-induced preadipocytes, preadipocytes were incubated with VD-MacCM. VD-MacCM were produced by incubating macrophages with ZK159222, ZK191784 and 1 α ,25(OH) $_2$ D $_3$.

Compared with MacCM-induced preadipocytes, (10 nM) 1 α ,25(OH) $_2$ D $_3$ -MacCM decreased secretion of the major pro-inflammatory cytokines by 25 ~ 50%, with the exception of IL-1 β . Likewise, (10 nM) ZK159222-MacCM and ZK191784-MacCM similarly reduced the major pro-inflammatory secretion by 33 ~ 54% and 23 ~ 51%. Furthermore, (1 μ M) ZK159222-MacCM and ZK191784-MacCM indistinguishably decreased the overall pro-inflammatory secretion by 30 ~ 63% and 24 ~ 44%, respectively (Figure 3A).

In parallel, (10 nM and 1 μ M) ZK159222-MacCM, (10 nM and 1 μ M) ZK191784-MacCM and (10 nM) 1 α ,25

Figure 2 Preadipocyte-specific effect of ZK159222, ZK191784 and $1\alpha,25(\text{OH})_2\text{D}_3$ on inflammatory and metabolic signaling in macrophage-induced preadipocytes. Preadipocytes were pre-incubated in preadipocyte growth medium or with ZK159222 (10 nM and 1 μM), ZK191784 (10 nM and 1 μM) or $1\alpha,25(\text{OH})_2\text{D}_3$ (10 nM) in preadipocyte growth medium for 48 h, and then incubated with 25% RPMI-1640 medium (the control) or 25% MacCM along with ZK159222 (10 nM and 1 μM), ZK191784 (10 nM and 1 μM) or $1\alpha,25(\text{OH})_2\text{D}_3$ (10 nM) in preadipocyte growth medium for a further 24 h. Preadipocytes were collected after the incubation. **(A)** The intracellular densities of relA, phosphorylated relA, p44/42 MAPK, phosphorylated p44/42 MAPK, p38 MAPK, phosphorylated p38 MAPK and vinculin were measured using Western blotting. The phosphorylation levels of **(B)** relA, **(C)** p44/42 MAPK and **(D)** p38 MAPK are shown. Data were analyzed using one-way ANOVA. The results are shown as means $\pm$ SEM for groups of 3 and confirmed by 3 independent experiments. A significant difference to control is indicated by * ($p < 0.05$) and *** ($p < 0.001$); to MacCM by ## ($p < 0.01$) and ### ($p < 0.001$); among ZK159222, ZK191784 and $1\alpha,25(\text{OH})_2\text{D}_3$ by && ($p < 0.01$) and &&& ($p < 0.001$).

Panel A

Figure 3 Continued.

Panel B

Figure 3 Macrophage-specific effect of ZK159222, ZK191784 and 1 α ,25(OH)₂D₃ on the major pro-inflammatory cytokines secreted and expressed in macrophage-induced preadipocytes. Preadipocytes were incubated with 25% RPMI-1640 medium (the control), 25% MacCM or VD-MacCM in preadipocyte growth medium for 24 h. Supernatants and preadipocytes were collected after the incubation. (Panel **A**) The concentrations of (a) IL-1 β , (b) IL-6, (c) IL-8, (d) MCP-1 and (e) RANTES were measured using ELISA. (Panel **B**) The relative gene expression of (a) IL-1 β , (b) IL-6, (c) IL-8, (d) MCP-1 and (e) RANTES were measured using qPCR. Data were analyzed using one-way ANOVA. The results are shown as means $\pm$ SEM for groups of 6 and confirmed by 3 independent experiments. A significant difference to control is indicated by ***($p < 0.001$); to MacCM by #($p < 0.05$), ##($p < 0.01$) and ###($p < 0.001$); among VD-MacCM by &($p < 0.05$), &&($p < 0.01$) and &&&($p < 0.001$).

(OH)₂D₃-MacCM inhibited the overall pro-inflammatory gene expression by 25 ~ 52% and 33 ~ 59%, 34 ~ 78% and 41 ~ 67%, 39 ~ 76%, respectively. The overall anti-inflammatory effects achieved were largely similar, though (10 nM) ZK191784-MacCM appeared most potent in inhibiting the gene expression of IL-8 and RANTES, while least effective on IL-1 β expression (Figure 3B).

Discussion

Physiologically, macrophage-preadipocyte interactions influence especially adipogenesis, lipolysis and apoptosis, which are fundamental metabolic processes to maintain adipose tissue homeostasis.^{26,27} During metaflammation, infiltration of excess M1 macrophages mobilize preadipocytes in paracrine/autocrine manners to disrupt adipose tissue

homeostasis, which might make a critical contribution to MetS.^{3,4,27,28} Hence, in this study, the metaflammatory responses were stimulated in macrophage-induced preadipocytes and measured only in supernatant/lysate extracted from the preadipocytes, since they are the progenitor of adipose tissue, rather than macrophages.²⁷ The current results revealed that secretion and gene expression of the major pro-inflammatory cytokines were significantly enhanced in macrophage-induced preadipocytes.

1 α ,25(OH)₂D₃ has been shown to improve inflammatory as well as metabolic biomarkers of MetS,²⁹ but there still is a long way to its clinical translation, which may be dependent upon the development of advantageous synthetic analogs and research to unravel their immunometabolic effects and mechanism of action.³⁰ The 1 α ,25(OH)₂D₃ analogs

ZK159222 and ZK191784 have manifested a number of tissue-specific immunomodulatory actions,^{31–33} but limited data are available on adipose tissue. In this study, preadipocyte and macrophage-specific effects of ZK159222 and ZK191784 on metaflammatory responses in macrophage-induced preadipocytes were thoroughly explored. $1\alpha,25(\text{OH})_2\text{D}_3$ served as the positive control since we previously demonstrated that it acts on preadipocytes to attenuate the metaflammatory responses in macrophage-induced preadipocytes.⁹ The present results show that ZK159222 and ZK191784 act on preadipocytes and macrophages to attenuate the metaflammatory responses in macrophage-induced preadipocytes (Figure 4). Although some differences in effects were obvious, both synthetic analogs not only decreased secretion and gene expression of the major pro-inflammatory cytokines in macrophage-induced preadipocytes as effectively as $1\alpha,25(\text{OH})_2\text{D}_3$, but also displayed distinct anti-inflammatory advantages at high concentrations, for preadipocyte apoptosis was not induced. Limitations of this study include the fact that we focused our assessment of the metaflammatory response on pro-

inflammatory cytokines. The cytokine array results revealed that $1\alpha,25(\text{OH})_2\text{D}_3$ increased serpin-E1 secreted from macrophage-induced preadipocytes. Overexpression of serpin-E1 has been suggested to show some beneficial effects on adipose tissue in metabolic syndrome.³⁴ However, IL-1RA, which acts as the inhibitor of IL-1 β ,³⁵ was paradoxically decreased (Supplementary Figure). Therefore, the effects of the synthetic analogs on anti-inflammatory cytokines during adipose tissue metaflammation should be considered in the future.

As a crucial inflammatory signaling activated during metaflammation, the NF- κ B/reI α integrates with metabolism to disrupt adipose tissue homeostasis and contribute to MetS.^{22,36} Moreover, MAPK has been suggested to be an important metabolic signaling to provoke MetS when inappropriately activated.²⁴ Specifically, p44/42 and p38 MAPK function in adipose tissue to regulate adipogenesis and lipolysis, which are characteristically disordered in MetS.^{37–40} Only preadipocyte-specific modulating effects on NF- κ B and MAPK signaling in macrophage-induced preadipocytes were measured in this study, since

Figure 4 ZK159222 and ZK191784 show anti-inflammatory properties in macrophage-induced preadipocytes via modulating the NF- κ B and MAPK signaling, but their effects on adipose tissue homeostasis remain to be explored. White adipose tissue is composed of mature adipocytes and a stromal vascular fraction containing preadipocytes and macrophages. During metaflammation, excessive infiltration of M1 macrophages induces preadipocytes to secrete and express major pro-inflammatory cytokines including IL-1 β , IL-6, IL-8, MCP-1 and RANTES, thereby contributing to disruption of adipose tissue homeostasis. Intriguingly, the synthetic $1\alpha,25(\text{OH})_2\text{D}_3$ analogs ZK159222 and ZK191784 act on preadipocytes and macrophages to attenuate the metaflammatory responses in preadipocytes, and the anti-inflammatory actions are exerted by de-phosphorylating inflammatory and metabolic signaling including reI α /NF- κ B, p44/42 and p38 MAPK. Moreover, macrophage–preadipocyte interactions influence adipogenesis, apoptosis and lipolysis to maintain adipose tissue homeostasis. Hence, in future studies, it would be interesting to investigate the effects of these analogs on the fundamental metabolic processes in adipose tissue.

not only preadipocytes are the progenitor of adipose tissue, but also were directly pre/incubated with the synthetic analogs.²⁷ The results revealed that the phosphorylation of *relA*, p44/42 and p38 MAPK were increased in macrophage-induced preadipocytes. $1\alpha,25(\text{OH})_2\text{D}_3$ acted on preadipocytes to decrease the phosphorylation of *relA*, p44/42 and p38 MAPK in macrophage-induced preadipocytes. ZK159222 and ZK191784 also de-phosphorylated these inflammatory and metabolic signaling, but most effectively when used at high concentrations. Last but not least, it would be interesting in future studies to investigate the effects of these analogs on those fundamental metabolic processes in adipose tissue (Figure 4).

Conclusion

The $1\alpha,25(\text{OH})_2\text{D}_3$ analogs ZK159222 and ZK191784 act on macrophages and preadipocytes to attenuate secretion and gene expression of the major pro-inflammatory cytokines in macrophage-induced preadipocytes, via decreasing phosphorylation of NF- κ B/*relA*, p44/42 and p38 MAPK.

Abbreviations

IL, interleukin; MacCM, macrophage-conditioned medium; MAPK, mitogen-activated protein kinase; MCP, monocyte chemoattractant protein; MetS, metabolic syndrome (MetS); RANTES, regulated on activation, normal T cell expressed and secreted.

Acknowledgments

Dr Chen Bing (formerly of the Institute of Ageing and Chronic Disease, University of Liverpool – now retired) co-conceived and co-designed the study, and provided ongoing advice during its conduct.

Author Contributions

JZ made substantial contributions to conception and design, acquisition of data. JW supervised the major findings. JW and JZ analyzed and interpreted the data. JZ drafted the article. JW revised it critically for important intellectual content. All the authors gave final approval of the version to be published; and agreed to be accountable for all aspects of the work.

Funding

This work was supported by the China Scholarship Council, with a grant awarded to Jingjing Zhu (No. 201306920002).

Disclosure

Professor John PH Wilding reports grants, personal fees and consultancy fees paid to the University of Liverpool from Astra Zeneca and Novo Nordisk; personal fees and consultancy fees paid to the University of Liverpool from Boehringer Ingelheim, Janssen, Mundipharma, Napp and Sanofi; and consultancy fees paid to the University of Liverpool from Astellas, Eli Lilly, Rhythm Pharma and Wilmington Healthcare, outside the submitted work. The authors report no other conflicts of interest in this work.

References

1. Samson SL, Garber AJ. Metabolic syndrome. *Endocrinol Metab Clin North Am*. 2014;43(1):1–23. doi:10.1016/j.ecl.2013.09.009
2. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. *Obes Rev*. 2015;16(1):1–12. doi:10.1111/obr.12229
3. Torres S, Fabersani E, Marquez A, Gauffin-Cano P. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics. *Eur J Nutr*. 2019;58(1):27–43. doi:10.1007/s00394-018-1790-2
4. Grundy SM. Adipose tissue and metabolic syndrome: too much, too little or neither. *Eur J Clin Invest*. 2015;45(11):1209–1217. doi:10.1111/eci.12519
5. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature*. 2017;542(7640):177–185. doi:10.1038/nature21363
6. Lin Z, Li W. The roles of Vitamin D and its analogs in inflammatory diseases. *Curr Top Med Chem*. 2016;16(11):1242–1261. doi:10.2174/1568026615666150915111557
7. Abbas MA. Physiological functions of Vitamin D in adipose tissue. *J Steroid Biochem Mol Biol*. 2017;165(Pt B):369–381. doi:10.1016/j.jsbmb.2016.08.004
8. Zhu J, Bing C, Wilding JPH. Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 β -stimulated human white preadipocytes via modulating the NF- κ B and unfolded protein response pathways. *Biochem Biophys Res Commun*. 2018;503(2):1049–1056. doi:10.1016/j.bbrc.2018.06.115
9. Zhu J, Bing C, Wilding JPH. $1\alpha,25(\text{OH})_2\text{D}_3$ attenuates IL-6 and IL-1 β -mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF- κ B signaling pathways. *Diabetol Metab Syndr*. 2019;11:9. doi:10.1186/s13098-019-0405-2
10. Berridge MJ. Vitamin D reactive oxygen species and calcium signaling in ageing and disease. *Philos Trans R Soc Lond B Biol Sci*. 2016;371:1700. doi:10.1098/rstb.2015.0434
11. Jones G, Kaufmann M. Update on pharmacologically-relevant vitamin D analogues. *Br J Clin Pharmacol*. 2019;85(6):1095–1102. doi:10.1111/bcp.13781
12. Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. *Proc Natl Acad Sci U S A*. 2004;101(13):4560–4565. doi:10.1073/pnas.0400983101
13. Ding C, Wilding JP, Bing C. Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes. *Endocrinol Metab Genet*. 2016;1:1–8. doi:10.15761/EMG.1000001
14. Feroze-Merzoug F, Berquin IM, Dey J, Chen YQ. Peptidylprolyl isomerase A (PPIA) as a preferred internal control over GAPDH and beta-actin in quantitative RNA analyses. *BioTechniques*. 2002;32(4):776–778, 780, 782. doi:10.2144/02324st03

15. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc.* 2008;3(6):1101–1108. doi:10.1038/nprot.2008.73
16. Koenen TB, Stienstra R, van Tits LJ, et al. The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. *Endocrinology.* 2011;152(10):3769–3778. doi:10.1210/en.2010-1480
17. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. *Inflam Res.* 2009;58(11):727–736. doi:10.1007/s00011-009-0060-4
18. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. *J Lipid Res.* 2008;49(9):1894–1903. doi:10.1194/jlr.M800132-JLR200
19. Kim CS, Park HS, Kawada T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. *Int J Obes.* 2006;30(9):1347–1355. doi:10.1038/sj.ijo.0803259
20. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. *J Clin Invest.* 2006;116(1):115–124. doi:10.1172/JCI24335
21. Kitade H, Sawamoto K, Nagashimada M, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. *Diabetes.* 2012;61(7):1680–1690. doi:10.2337/db11-1506
22. Catrysse L, van Loo G. Inflammation and the metabolic syndrome: the tissue-specific functions of NF-kappaB. *Trends Cell Biol.* 2017;27(6):417–429. doi:10.1016/j.tcb.2017.01.006
23. Leon-Pedroza JI, Gonzalez-Tapia LA, Del Olmo-Gil E, Castellanos-Rodriguez D, Escobedo G, Gonzalez-Chavez A. [Low-grade systemic inflammation and the development of metabolic diseases: from the molecular evidence to the clinical practice]. *Cir Cir.* 2015;83(6):543–551. Spanish. doi:10.1016/j.circir.2015.05.041
24. Gehart H, Kumpf S, Ittner A, Ricci R. MAPK signalling in cellular metabolism: stress or wellness? *EMBO Rep.* 2010;11(11):834–840. doi:10.1038/embor.2010.160
25. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev.* 2011;75(1):50–83. doi:10.1128/MMBR.00031-10
26. Bertheuil N, Chaput B, Menard C, et al. Adipose mesenchymal stromal cells: definition, immunomodulatory properties, mechanical isolation and interest for plastic surgery. *Ann Chir Plast Esthet.* 2019;64(1):1–10. doi:10.1016/j.anplas.2018.07.005
27. Sorisky A, Molgat AS, Gagnon A. Macrophage-induced adipose tissue dysfunction and the preadipocyte: should I stay (and differentiate) or should I go? *Advan Nutri.* 2013;4(1):67–75. doi:10.3945/an.112.003020
28. Choe SS, Huh JY, Hwang JJ, Kim JI, Kim JB. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. *Front Endocrinol (Lausanne).* 2016;7:30. doi:10.3389/fendo.2016.00030
29. Slusher AL, McAllister MJ, Huang CJ. A therapeutic role for vitamin D on obesity-associated inflammation and weight-loss intervention. *Inflam Res.* 2015;64(8):565–575. doi:10.1007/s00011-015-0847-4
30. Leyssens C, Verlinden L, Verstuyf A. The future of vitamin D analogs. *Front Physiol.* 2014;5:122. doi:10.3389/fphys.2014.00122
31. Toell A, Gonzalez MM, Ruf D, Steinmeyer A, Ishizuka S, Carlberg C. Different molecular mechanisms of vitamin D(3) receptor antagonists. *Mol Pharmacol.* 2001;59(6):1478–1485. doi:10.1124/mol.59.6.1478
32. Nijenhuis T, van der Eerden BC, Zugel U, et al. The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist. *FASEB J.* 2006;20(12):2171–2173. doi:10.1096/fj.05-5155fje
33. van der Eerden BC, Fratzl-Zelman N, Nijenhuis T, et al. The vitamin D analog ZK191784 normalizes decreased bone matrix mineralization in mice lacking the calcium channel TRPV5. *J Cell Physiol.* 2013;228(2):402–407. doi:10.1002/jcp.24144
34. Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. *Br J Haematol.* 2012;157(3):291–298. doi:10.1111/j.1365-2141.2012.09074.x
35. Boraschi D, Italiani P, Weil S, Martin MU. The family of the interleukin-1 receptors. *Immunol Rev.* 2018;281(1):197–232.
36. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. *Trends Cell Biol.* 2012;22(11):557–566. doi:10.1016/j.tcb.2012.08.001
37. Hong S, Song W, Zushin PH, et al. Phosphorylation of Beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes. *Mol Metab.* 2018;12:25–38. doi:10.1016/j.molmet.2018.03.012
38. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. *J Recept Signal Transduct Res.* 2015;35(6):600–604. doi:10.3109/10799893.2015.1030412
39. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. *Biochem J.* 2010;429(3):403–417. doi:10.1042/BJ20100323
40. Fang H, Judd RL. Adiponectin regulation and function. *Compr Physiol.* 2018;8(3):1031–1063.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>